Granted Patent
B2
US 12,497,615 · App. 17/605,955 · Granted Dec 16, 2025
Nucleic acid compositions and methods of multi-exon skipping
Inventors:
Beatrice Diana Darimont (San Diego, CA); Yunyu Shi (La Jolla, CA); Michael Caramian Cochran (La Jolla, CA); Andrew John Geall (Carlsbad, CA)
Assignee:
AVIDITY BIOSCIENCES, INC.
C12N15/113A61K31/7088C12N15/111C12N2310/11C12N2310/3145C12N2310/3183C12N2310/3233C12N2310/3519C12N2320/33
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Disclosed herein are oligonucleotide conjugates and pharmaceutical compositions for inducing multi-exon skipping. In some instances, also disclosed herein are methods of treating a muscular dystrophy, including treating Duchenne muscular dystrophy or Becker muscular dystrophy.
Claims (17)
1 . An oligonucleotide conjugate comprising a first oligonucleotide linked to a second oligonucleotide by a polymer comprising polyethylene glycol (PEG), wherein a 5′ end of the first oligonucleotide is linked to one end of the polymer, and a 3′ end of the second oligonucleotide is linked to another end of the polymer, wherein the first oligonucleotide hybridizes to a region in a first exon of a pre-mRNA and the second oligonucleotide hybridizes to a region in a second exon of the pre-mRNA, wherein the first exon and the second exon are not the same exon, wherein the oligonucleotide conjugate induces splicing out of an exon-containing lariat from the pre-mRNA to generate a processed mRNA, and wherein the processed mRNA encodes a truncated and functional protein.
2 . The oligonucleotide conjugate of claim 1 , wherein the first oligonucleotide or the second oligonucleotide is from about 10 to about 50 nucleotides in length or from about 10 to about 30 nucleotides in length.
3 . The oligonucleotide conjugate of claim 1 , wherein the first oligonucleotide or the second oligonucleotide comprises one or more phosphorodiamidate morpholino oligomers (PMO).
4 . The oligonucleotide conjugate of claim 1 , wherein the PEG comprises at least 2 repeating ethylene oxide units.
5 . The oligonucleotide conjugate of claim 1 , wherein the oligonucleotide conjugate is further conjugated to an anti-transferrin receptor antibody or antigen binding fragments thereof.
6 . The oligonucleotide conjugate of claim 1 , wherein the pre-mRNA encodes dystrophin, wherein the dystrophin comprises a mutation, a deletion, an insertion, or a combination thereof.
7 . The oligonucleotide conjugate of claim 6 , wherein the first exon is exon 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, or 51 of DMD, and wherein the second exon is exon 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, or 63 of DMD, and the first exon is at least 2 exons apart from the second exon.
8 . A method of inducing multiple exon skipping from a pre-mRNA, comprising:
contacting the pre-mRNA in a cell with an oligonucleotide conjugate comprising a first oligonucleotide linked to a second oligonucleotide by a polymer comprising polyethylene glycol (PEG), wherein a 5′ end of the first oligonucleotide is linked to one end of the polymer, and a 3′ end of the second oligonucleotide is linked to another end of the polymer, wherein the first oligonucleotide hybridizes to a region in a first exon of the pre-mRNA and the second oligonucleotide hybridizes to a region in a second exon of the pre-mRNA, wherein the first exon and the second exon are not the same exon, wherein the oligonucleotide conjugate induces splicing out of an exon-containing lariat from the pre-mRNA to generate a processed mRNA, and wherein the processed mRNA encodes a truncated and functional protein.
9 . A method of treating a disease characterized by a defective protein function in a subject in need thereof, comprising:
administering to the subject a pharmaceutical composition comprising an oligonucleotide conjugate comprising a first oligonucleotide linked to a second oligonucleotide by a polymer comprising polyethylene glycol (PEG), wherein a 5′ end of the first oligonucleotide is linked to one end of the polymer, and a 3′ end of the second oligonucleotide is linked to another end of the polymer, wherein the first oligonucleotide hybridizes to a region in a first exon of a pre-mRNA and the second oligonucleotide hybridizes to a region in a second exon of the pre-mRNA, wherein the first exon and the second exon are not the same exon, wherein the oligonucleotide conjugate induces splicing out of an exon-containing lariat from the pre-mRNA to generate a processed mRNA, and wherein the processed mRNA encodes a truncated and functional protein, thereby treating the disease or condition in the subject.
10 . The method of claim 9 , wherein the disease or condition is Duchenne muscular dystrophy, Becker's muscular dystrophy, facioscapulohumeral muscular dystrophy, congenital muscular dystrophy, myotonic dystrophy, a neuromuscular disease, a genetic disease, cancer, a hereditary disease, or a cardiovascular disease.
11 . The method of claim 8 , wherein the first oligonucleotide or the second oligonucleotide comprises one or more phosphorodiamidate morpholino oligomers (PMO).
12 . The method of claim 8 , wherein the PEG comprises at least 2 repeating ethylene oxide units.
13 . The method of claim 8 , wherein the oligonucleotide conjugate is further conjugated to an anti-transferrin receptor antibody or antigen binding fragments thereof.
14 . The method of claim 8 , wherein the pre-mRNA encodes dystrophin, wherein the dystrophin comprises a mutation, a deletion, an insertion, or a combination thereof.
15 . The method of claim 8 , wherein the first exon is exon 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, or 51 of DMD, and wherein the second exon is exon 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, or 63 of DMD, and wherein the first exon is at least 2 exons apart from the second exon.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Oct 19, 2022
From: DARIMONT, BEATRICE DIANA; SHI, YUNYU; COCHRAN, MICHAEL CARAMIAN; GEALL, ANDREW JOHN
To: AVIDITY BIOSCIENCES, INC.
Reel/Frame 061468/0789 →
Continuity (2)
Provisional Application
62838888
· Apr 25, 2019
References Cited (392)
US 4694778A
· Learn et al.
· 1987
[cited by applicant]
US 5142047A
· Summerton et al.
· 1992
[cited by applicant]
US 5185444A
· Summerton et al.
· 1993
[cited by applicant]
US 5334711A
· Sproat et al.
· 1994
[cited by applicant]
US 5627053A
· Usman et al.
· 1997
[cited by applicant]
US 5716824A
· Beigelman et al.
· 1998
[cited by applicant]
US 5736557A
· Hofheinz et al.
· 1998
[cited by applicant]
US 5889136A
· Scaringe et al.
· 1999
[cited by applicant]
US 6008400A
· Scaringe et al.
· 1999
[cited by applicant]
US 6111086A
· Scaringe
· 2000
[cited by applicant]
US 6194551B1
· Idusogie et al.
· 2001
[cited by applicant]
US 6528624B1
· Idusogie et al.
· 2003
[cited by applicant]
US 6538124B1
· Idusogie et al.
· 2003
[cited by applicant]
US 6821783B1
· Comely et al.
· 2004
[cited by applicant]
US 6884869B2
· Senter et al.
· 2005
[cited by applicant]
US 7364731B2
· Idusogie et al.
· 2008
[cited by applicant]
US 7452987B2
· Giese et al.
· 2008
[cited by applicant]
US 7498298B2
· Doronina et al.
· 2009
[cited by applicant]
US 7833992B2
· Vargeese et al.
· 2010
[cited by applicant]
US 7850975B2
· Mullis
· 2010
[cited by applicant]
US 7893245B2
· Giese et al.
· 2011
[cited by applicant]
US 7923547B2
· Mcswiggen et al.
· 2011
[cited by applicant]
US 7943762B2
· Weller et al.
· 2011
[cited by applicant]
US 8084582B2
· Dahiyat et al.
· 2011
[cited by applicant]
US 8084598B1
· Bentwich
· 2011
[cited by applicant]
US 8090542B2
· Khvorova et al.
· 2012
[cited by applicant]
US 8202979B2
· Mcswiggen et al.
· 2012
[cited by applicant]
US 8273866B2
· Mcswiggen et al.
· 2012
[cited by applicant]
US 8288352B2
· Doronina et al.
· 2012
[cited by applicant]
US 8324370B2
· Giese et al.
· 2012
[cited by applicant]
US 8324371B2
· Popplewell et al.
· 2012
[cited by applicant]
US 8361979B2
· Aartsma-Rus et al.
· 2013
[cited by applicant]
US 8455634B2
· Wilton et al.
· 2013
[cited by applicant]
US 8461325B2
· Popplewell et al.
· 2013
[cited by applicant]
US 8501703B2
· Bennett et al.
· 2013
[cited by applicant]
US 8501930B2
· Rozema et al.
· 2013
[cited by applicant]
US 8591910B2
· Mullis
· 2013
[cited by applicant]
US 8604184B2
· Mullis et al.
· 2013
[cited by applicant]
US 8609105B2
· Senter et al.
· 2013
[cited by applicant]
US 8618277B2
· Beigelman et al.
· 2013
[cited by applicant]
US 8648185B2
· Mcswigen et al.
· 2014
[cited by applicant]
US 8697688B2
· Howard et al.
· 2014
[cited by applicant]
US 8895722B2
· Iversen et al.
· 2014
[cited by applicant]
US 8933215B2
· Giese et al.
· 2015
[cited by applicant]
US 8936910B2
· Mitsch et al.
· 2015
[cited by applicant]
US 8969526B2
· Baehner et al.
· 2015
[cited by applicant]
US 9078911B2
· Lu
· 2015
[cited by applicant]
US 9089614B2
· Lin et al.
· 2015
[cited by applicant]
US 9096877B2
· Johnson et al.
· 2015
[cited by applicant]
US 9139828B2
· Platenburg et al.
· 2015
[cited by applicant]
US 9175286B2
· Wilton et al.
· 2015
[cited by applicant]
US 9181551B2
· Mcswiggen et al.
· 2015
[cited by applicant]
US 9222092B2
· Giese et al.
· 2015
[cited by applicant]
US 9228187B2
· Wilton et al.
· 2016
[cited by applicant]
US 9234198B1
· Sazani et al.
· 2016
[cited by applicant]
US 9243245B2
· De Kimpe et al.
· 2016
[cited by applicant]
US 9243251B2
· Popplewell et al.
· 2016
[cited by applicant]
US 9243252B2
· Popplewell et al.
· 2016
[cited by applicant]
US 9249416B2
· Wilton et al.
· 2016
[cited by applicant]
US 9260471B2
· Cancilla et al.
· 2016
[cited by applicant]
US 9416361B2
· Iversen et al.
· 2016
[cited by applicant]
US 9434948B2
· Sazani et al.
· 2016
[cited by applicant]
US 9441229B2
· Wilton et al.
· 2016
[cited by applicant]
US 9447415B2
· Wilton et al.
· 2016
[cited by applicant]
US 9447417B2
· Sazani et al.
· 2016
[cited by applicant]
US 9481905B2
· Chen et al.
· 2016
[cited by applicant]
US 9499818B2
· Van Deutukom
· 2016
[cited by applicant]
US 9512424B2
· Watanabe et al.
· 2016
[cited by applicant]
US 9528109B2
· De Kimpe et al.
· 2016
[cited by applicant]
US 9605019B2
· Verdine et al.
· 2017
[cited by applicant]
US 9657294B2
· Beigelman et al.
· 2017
[cited by applicant]
US 9695211B2
· Wada et al.
· 2017
[cited by applicant]
US 9695423B2
· Giese et al.
· 2017
[cited by applicant]
US 9732344B2
· Beigelman et al.
· 2017
[cited by applicant]
US 9765338B2
· Bennett et al.
· 2017
[cited by applicant]
US 9771588B2
· Mcswiggen et al.
· 2017
[cited by applicant]
US 9796974B2
· Rajeev et al.
· 2017
[cited by applicant]
US 9890379B2
· De Kimpe et al.
· 2018
[cited by applicant]
US 9926557B2
· De Kimpe et al.
· 2018
[cited by applicant]
US 9982257B2
· Butler et al.
· 2018
[cited by applicant]
US 20020142980A1
· Thompson et al.
· 2002
[cited by applicant]
US 20110081362A1
· Elledge et al.
· 2011
[cited by applicant]
US 20110263686A1
· Wilton et al.
· 2011
[cited by applicant]
US 20110301218A1
· Bozzoni et al.
· 2011
[cited by applicant]
US 20120094299A1
· Ranum et al.
· 2012
[cited by applicant]
US 20120172415A1
· Voit et al.
· 2012
[cited by applicant]
US 20160298111A1
· Bestwick et al.
· 2016
[cited by applicant]
US 20160304864A1
· De Kimpe et al.
· 2016
[cited by applicant]
US 20160304877A1
· Swayze et al.
· 2016
[cited by applicant]
US 20170107512A1
· De Kimpe et al.
· 2017
[cited by applicant]
US 20180016574A1
· Bestwick et al.
· 2018
[cited by applicant]
US 20180028554A1
· Van Deutekom et al.
· 2018
[cited by applicant]
US 20180163209A1
· Bennett et al.
· 2018
[cited by applicant]
US 20180305689A1
· Sætrom et al.
· 2018
[cited by applicant]
US 20190177723A1
· Dickson
· 2019
[cited by applicant]
US 20190240346A1
· Sugo et al.
· 2019
[cited by applicant]
US 20190330626A1
· Rigo et al.
· 2019
[cited by applicant]
US 20200282074A1
· Levin
· 2020
[cited by examiner]
US 20220081689A1
· Rigo et al.
· 2022
[cited by applicant]
US 20220288218A1
· Yokota et al.
· 2022
[cited by applicant]
US 20230330128A1
· Van Deutekom et al.
· 2023
[cited by applicant]
US 20240358736A1
· Levin et al.
· 2024
[cited by applicant]
US 20250161344A1
· Levin et al.
· 2025
[cited by applicant]
US 20250170260A1
· Levin et al.
· 2025
[cited by applicant]
CN 106459955A
· 2017
[cited by applicant]
EP 0336675A1
· 1989
[cited by applicant]
EP 0334656B1
· 1994
[cited by applicant]
EP 1579015A2
· 2005
[cited by applicant]
EP 1068241B1
· 2007
[cited by applicant]
EP 2119783A1
· 2009
[cited by applicant]
EP 2049664B1
· 2011
[cited by applicant]
EP 2278004B1
· 2012
[cited by applicant]
EP 2344637B1
· 2014
[cited by applicant]
EP 1423406B2
· 2015
[cited by applicant]
EP 3031920A1
· 2016
[cited by applicant]
EP 2421971B1
· 2016
[cited by applicant]
EP 2287306B2
· 2016
[cited by applicant]
EP 3030658A4
· 2017
[cited by applicant]
EP 2287305B2
· 2017
[cited by applicant]
EP 2486141B1
· 2018
[cited by applicant]
EP 2902406B1
· 2018
[cited by applicant]
EP 2595664B1
· 2018
[cited by applicant]
WO WO9104753A1
· 1991
[cited by applicant]
WO WO9207065A1
· 1992
[cited by applicant]
WO WO9315187A1
· 1993
[cited by applicant]
WO WO9726270A2
· 1997
[cited by applicant]
WO WO9734631A1
· 1997
[cited by applicant]
WO WO9813526A1
· 1998
[cited by applicant]
WO WO0149698A1
· 2001
[cited by applicant]
WO WO2004009851A2
· 2004
[cited by applicant]
WO WO2004083446A2
· 2004
[cited by applicant]
WO WO2006000057A1
· 2006
[cited by applicant]
WO WO2008036127A2
· 2008
[cited by applicant]
WO WO2009054725A2
· 2009
[cited by applicant]
WO WO2009099942A2
· 2009
[cited by applicant]
WO WO2009099991A2
· 2009
[cited by applicant]
WO WO2009139630A2
· 2009
[cited by applicant]
WO WO2009139630A9
· 2009
[cited by applicant]
WO WO2009144481A2
· 2009
[cited by applicant]
WO WO2010048586A1
· 2010
[cited by applicant]
WO WO2010050801A1
· 2010
[cited by applicant]
WO WO2011130371A1
· 2011
[cited by applicant]
WO WO2011150408A2
· 2011
[cited by applicant]
WO WO2013166155A1
· 2013
[cited by applicant]
WO WO2014007620A2
· 2014
[cited by applicant]
WO WO2014080251A1
· 2014
[cited by applicant]
WO WO2014140317A2
· 2014
[cited by applicant]
WO WO2014144978A2
· 2014
[cited by applicant]
WO WO2014145090A1
· 2014
[cited by applicant]
WO WO2014177042A1
· 2014
[cited by applicant]
WO WO2014197748A2
· 2014
[cited by applicant]
WO WO2014197854A1
· 2014
[cited by applicant]
WO WO2015021457A2
· 2015
[cited by applicant]
WO WO2015038426A1
· 2015
[cited by applicant]
WO WO2015057699A2
· 2015
[cited by applicant]
WO WO2015069587A2
· 2015
[cited by applicant]
WO WO2015107425A2
· 2015
[cited by applicant]
WO WO2016187425A1
· 2016
[cited by applicant]
WO WO2016207240A1
· 2016
[cited by applicant]
WO WO2017148879A1
· 2017
[cited by applicant]
WO WO2017173408A1
· 2017
[cited by applicant]
WO WO2017192679A1
· 2017
[cited by applicant]
WO WO2017221883A1
· 2017
[cited by applicant]
WO WO2018002812A1
· 2018
[cited by applicant]
WO WO2018129384A1
· 2018
[cited by applicant]
WO WO2019060775A1
· 2019
[cited by applicant]
WO WO2019200185A1
· 2019
[cited by applicant]
WO WO2020132584A1
· 2020
[cited by applicant]
WO WO2020219820A1
· 2020
[cited by applicant]
WO WO2021108640A1
· 2021
[cited by applicant]
WO WO2021113390A1
· 2021
[cited by applicant]
WO WO2021142307A1
· 2021
[cited by applicant]
WO WO2022020107A1
· 2022
[cited by applicant]
WO WO2023283615A1
· 2023
[cited by applicant]
WO WO2023121444A1
· 2023
[cited by applicant]
WO WO2023121445A1
· 2023
[cited by applicant]
WO WO2023141710A1
· 2023
[cited by applicant]
WO WO2023171820A1
· 2023
[cited by applicant]
U.S. Appl. No. 16/649,572 Office Action dated Feb. 22, 2023.
[cited by applicant]
Takeda, Shin'ichi. Exon-skipping therapy for Duchenne muscular dystrophy. Clinical Neurology 51:914-916 (2011) (English Abstract).
[cited by applicant]
U.S. Appl. No. 16/649,572 Office Action dated Apr. 16, 2024.
[cited by applicant]
U.S. Appl. No. 16/649,572 Office Action dated Oct. 30, 2024.
[cited by applicant]
Brain and Development 42:117-123 (2010).
[cited by applicant]
Aartsma-Rus et al., Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense. American Journal of Human Genetics 74(1):83-92 (2004).
[cited by applicant]
Aartsma-Rus et al. Guidelines for antisense oligonucleotide design and insight into splice-modulating mechanisms. Mol Ther 17(3):548-53 (2009).
[cited by applicant]
Aartsma-Rus et al. Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy. Neuromuscul Disord. 12 Suppl 1:S71-7 (2002).
[cited by applicant]
Abramova et al. Novel oligonucleotide analogues based on morpholino nucleoside subunits-antisense technologies: new chemical possibilities. Indian Journal of Chemistry 48B:1721-1726 (2009).
[cited by applicant]
Agarwal et al. A Pictet-Spengler ligation for protein chemical modification. PNAS 110(1):46-51 (2013).
[cited by applicant]
Albarran et al. Efficient intracellular delivery of a pro-apoptotic peptide with a pH-responsive carrier. React Funct Polym 71:261-265 (2011).
[cited by applicant]
Arechavala-Gomeza et al. Comparative analysis of antisense oligonucleotide sequences for targeted skipping of exon 51 during dystrophin pre-mRNA splicing in human muscle. Hum Gene Ther. 18(9):798-810 (2007).
[cited by applicant]
Axup et al. Synthesis of site-specific antibody-drug conjugates using unnatural amino acids. PNAS 109(40):16101-16106 (2012).
[cited by applicant]
Baumer et al. Antibody-mediated delivery of anti-KRAS-siRNA in vivo overcomes therapy resistance in colon cancer. Clin Can Res 21(6):1383-1394 (2015).
[cited by applicant]
Beduneau et al. Design of targeted lipid nanocapsules by conjugation of whole antibodies and antibody Fab' fragments. Biomaterials 28(33):4978-4990 (2007).
[cited by applicant]
Beigelman et al. Chemical modification of hammerhead ribozymes. Catalytic activity and nuclease resistance. J Biol Chem 270:25702-25708 (1995).
[cited by applicant]
Bell et al. Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non-Small-Cell Lung Cancer: Molecular Analysis of the Ideal/Intact Gefitinib Trials. J Clin Oncol 23(31):8081-8092 (2005).
[cited by applicant]
Bird et al. Single-chain antigen-binding proteins. Science 242:423-442 (1988).
[cited by applicant]
Blaney et al. Traceless solid-phase organic synthesis. Chem. Rev. 102:2607-2024 (2002.
[cited by applicant]
Bulmus et al. A new pH-responsive and glutathione-reactive, endosomal membrane-disruptive polymeric carrier for intracellular delivery of biomolecular drugs. J Controlled Release 93:105-120 (2003).
[cited by applicant]
Burke et al. siRNA-mediated knockdown of P450 oxidoreductase in rats: a tool to reduce metabolism by CYPs and increase exposure of high clearance compounds. Pharm. Res. 31(12):3445-3460 (2014).
[cited by applicant]
Burlina et al. Chemical engineering of RNase resistant and catalytically active hammerhead ribozymes. Bioorg Med Chem 5:1999-2010 (1997).
[cited by applicant]
Casi et al. Site-specific traceless coupling of potent cytotoxic drugs to recombinant antibodies for pharmacodelivery. J Am Chem Soc 134(13):5887-5892 (2012).
[cited by applicant]
Castaneda et al. Acid-cleavable thiomaleamic acid linker for homogeneous antibody-drug conjugation, Chem. Commun. 49:8187-8189 (2013).
[cited by applicant]
Chen et al. Strand-specific 5′-O-methylation of siRNA duplexes controls guide strand selection and targeting specificity. RNA 14:263-274 (2008).
[cited by applicant]
Clackson et al. Making antibody fragments using phage display libraries. Nature 352(6336):624-628 (1991).
[cited by applicant]
Colberre-Garapin et al. A new dominant hybrid selective marker for higher eukaryotic cells. J Mol Biol 150:1-14 (1981).
[cited by applicant]
Cole et al. The EBV-hybridoma technique and its application to human lung cancer. In, Monoclonal Antibodies and Cancer Therapy (vol. 27, UCLA Symposia on Molecular and Cellular Biology, New Series) (eds. R.A. Reisfeld a…
[cited by applicant]
Crouse et al. Expression and amplification of engineered mouse dihydrofolate reductase minigenes. Mol Cell Biol 3(2):257-266 (1983).
[cited by applicant]
Cuellar et al. Systematic evaluation of antibody-mediated siRNA delivery using an industrial platform of THIOMAB-siRNA conjugates. Nucleic Acids Res 43(2):1189-1203 (2015).
[cited by applicant]
Darimont et al. 8-05 Abstract: A novel Antibody-Oligonucleotide Conjugate (AOC) platform enables efficient regulation of muscle targets in mice. Journal of Cachexia, Sarcopenia and Muscle 8:999-1080 (2017).
[cited by applicant]
Dawson et al. Modulation of Reactivity in Native Chemical Ligation through the Use of Thiol Additives. J. Am. Chem. Soc. 119:4325-4329 (1997).
[cited by applicant]
Dawson et al. Synthesis of proteins by native chemical ligation. Science 266(5186):776-779 (1994).
[cited by applicant]
De Angelis et al. Chimeric snRNA molecules carrying antisense sequences against the splice junctions of exon 51 of the dystrophin pre-mRNA induce exon skipping and restoration of a dystrophin synthesis in Delta 48-50 DM…
[cited by applicant]
Debinski et al. Monovalent immunotoxin containing truncated form of Pseudomonas exotoxin as potent antitumor agent. Cancer Research 52(19):5379-5385 (1992).
[cited by applicant]
Deleavey et al. Designing chemically modified oligonucleotides for targeted gene silencing. Chem Biol. 19(8):937-954 (2012).
[cited by applicant]
Dietel et al. A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance. Cancer Gene Ther 22(9):417-430 (2015).
[cited by applicant]
Dimasi et al. Development of a trispecific antibody designed to simultaneously and efficiently target three different antigens on tumor cells. Mol Pharm 12(9):3490-3501 (2015).
[cited by applicant]
Domingo et al. Transferrin receptor as a target for antibody-drug conjugates. Methods in Enzymology 112:238-247 (1985).
[cited by applicant]
Duncan et al. A polymer-Triton X-100 conjugate capable of pH-dependent red blood cell lysis: a model system illustrating the possibility of drug delivery within acidic intracellular compartments. J Drug Target 2:341-347…
[cited by applicant]
Earnshaw et al. Modified oligoribonucleotides as site-specific probes of RNA structure and function. Biopolymers (Nucleic Acid Sciences) 48:39-55 (1998).
[cited by applicant]
Echigoya et al. In Silico Screening Based on Predictive Algorithms as a Design Tool for Exon Skipping Oligonucleotides in Duchenne Muscular Dystrophy. PLoS One 10(3):e0120058 (2015).
[cited by applicant]
El-Sayed et al. Rational design of composition and activity correlations for pH-responsive and glutathione-reactive polymer therapeutics. J Control Release 104:417-427 (2005).
[cited by applicant]
Feener et al. Alternative splicing of human dystrophin mRNA generates isoforms at the carboxy terminus. Nature 338:509-511 (Apr. 6, 1989).
[cited by applicant]
Ferreiro et al. Asymptomatic Becker muscular dystrophy in a family with a multiexon deletion. Muscle Nerve 39:239-243 (2009).
[cited by applicant]
Flanary et al. Antigen delivery with poly(propylacrylic acid) conjugation enhanced MHC-1 presentation and T-cell activation. Bioconjugate Chem. 20:241-248 (2009).
[cited by applicant]
Gao et al. Effective Dystrophin Restoration by a Novel Muscle-Homing Peptide-Morpholino Conjugate in Dystrophin-Deficient mdx Mice. Mol Ther. 22(7):1333-1341 (2014).
[cited by applicant]
Gaziova et al. Chemically defined polyethylene glycol siRNA conjugates with enhanced gene silencing effect. Bioorg Med Chem 22(7):2320-2326 (2014).
[cited by applicant]
Goldspiel et al. Human gene therapy. Clin Pharm 12:488-505 (1993).
[cited by applicant]
Gooding et al. Oligonucleotide conjugates—Candidates for gene silencing therapeutics. Eur J Pharm Biopharm. 107:321-40 (2016).
[cited by applicant]
Griffey et al. 2′-0-aminopropyl ribonucleotides: a zwitterionic modification that enhances the exonuclease resistance and biological activity of antisense oligonucleotides, J. Med. Chem. 39(26):5100-5109 (1997).
[cited by applicant]
Hackeng et al. Protein synthesis by native chemical ligation: Expanded scope by using straightforward methodology. PNAS USA 96:10068-10073 (1999).
[cited by applicant]
Hanes et al. In vitro selection and evolution of functional proteins by using ribosome display. PNAS USA 94:4937-4942 (1997).
[cited by applicant]
Hejesen et al. A traceless aryl-triazene linker for DNA-directed chemistry. Org Biomol Chem 11(15):2493-2497 (2013).
[cited by applicant]
Henry et al. pH-responsive poly(styrene-alt-maleic anhydride) alkylamide copolymers for intracellular drug delivery. Biomacromolecules 7:2407-2414 (2006).
[cited by applicant]
Hitachi et al. Role of microRNAs in skeletal muscle hypertrophy. Front Physiol 16(4):408 (2014).
[cited by applicant]
Hoffman et al. Restoring Dystrophin Expression in Duchenne Muscular Dystrophy Muscle: Progress in Exon Skipping and Stop Codon Read Through. Am J Pathol 179(1):12-22 (2011).
[cited by applicant]
Hu et al. Site-specific Antibody-polymer Conjugates for siRNA Delivery. J Am Chem Soc 135(37):13885-13891 (2013).
[cited by applicant]
Huang et al. Mechanisms of resistance to EGFR tyrosine kinase inhibitors. Acta Pharma Sinica B 5(5):390-401 (2015).
[cited by applicant]
Hudson et al. Cellular delivery of hammerhead ribozymes conjugated to a transferrin receptor antibody. Int J Pharmaceuticals 182(1):49-58 (1999).
[cited by applicant]
Huse et al. Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda. Science 246(4935):1275-1281 (1989).
[cited by applicant]
Huston et al. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in
[cited by applicant]
Ishikawa et al. Preparation of monomeric Fab'—horseradish peroxidase conjugate using thiol groups in the hinge and its evaluation in enzyme immunoassay and immunohistochemical staining. Ann N Y Acad Sci. 420:74-89 (1983…
[cited by applicant]
Iversen et al. Optimized siRNA-PEG conjugates for extended blood circulation and reduced urine excretion in mice. Theranostics 3(3):201-209 (2013).
[cited by applicant]
Jancik et al. Clinical relevance of KRAS in human cancers. J Biomed Biotechnol 2010:150960 (13 pgs.) (2010).
[cited by applicant]
Jearawiriyapaisarn et al. Sustained Dystrophin Expression Induced by Peptide-conjugated Morpholino Oligomers in the Muscles of mdx Mice. Mol Ther. 16(9): 1624-1629 (2008).
[cited by applicant]
Jones et al. Poly(2-alkylacrylic acid) polymers deliver molecules to the cytosol by pH-sensitive disruption of endosomal vesicles. Biochem J 372:65-75 (2003).
[cited by applicant]
Karpeisky et al. Highly efficient synthesis of 2′-O-amino nucleosides and their incorporation in hammerhead ribozymes. Tetrahedron Lett 39:1131-1134 (1998).
[cited by applicant]
Khormaee et al. Endosomolytic anionic polymer for the cytoplasmic delivery of siRNAs in localized in vivo applications. Adv Funct Mater 23:565-574 (2013).
[cited by applicant]
Kim et al. PEG conjugated VEGF siRNA for anti-angiogenic gene therapy. J Cont Rel 116:123-129 (2006).
[cited by applicant]
Kohler et al. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495-497 (1975).
[cited by applicant]
Koizumi. ENA oligonucleotides as therapeutics. Curr Opin Mol Ther 8(2):144-149 (2006).
[cited by applicant]
Kontermann et al. Bispecific antibodies. Drug Discov Today 20(7):838-847 (2015).
[cited by applicant]
Kozbor et al. The production of monoclonal antibodies from human lymphocytes. Immunology Today 4:72-79 (1983).
[cited by applicant]
Kutmeier et al. Assembly of humanized antibody genes from synthetic oligonucleotides using a single-round PCR. BioTechniques 17:242 (1994).
[cited by applicant]
Lee et al. Antisense PMO cocktails effectively skip dystrophin exons 45-55 in myotubes transdifferentiated from DMD patient fibroblasts. PLoS One 13(5):e0197084 (2018).
[cited by applicant]
Lee et al. Direct Reprogramming of Human DMD Fibroblasts into Myotubes for In Vitro Evaluation of Antisense-Mediated Exon Skipping and Exons 45-55 Skipping Accompanied by Rescue of Dystrophin Expression. Methods Mol Bio…
[cited by applicant]
Leigh et al. The Human Plasma Proteome: History, Character, and Diagnostic Prospects. Mol Cell Proteomics 1:845-867 (2002).
[cited by applicant]
Levin. Targeting Therapeutic Oligonucleotides. N Engl J Med 376:86-88 (2017).
[cited by applicant]
Loakes. Survey and summary: The applications of universal DNA base analogues. Nucleic Acids Research 29:2437-2447 (2001).
[cited by applicant]
Loh et al. A Survey of siRNA Nanoscal Delivery Patents. 11 Nanotechnology Law & Bus. (pp. 29-37) (2014).
[cited by applicant]
Lowy et al., Isolation of transforming DNA: Cloning the hamster aprt gene. Cell 22:817-823 (1980).
[cited by applicant]
Lyon et al. Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates. Nat. Biotechnol. 32(10):1059-1062 (2014).
[cited by applicant]
Martinez et al. Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell 110(5):563-574 (2002).
[cited by applicant]
McEnaney et al. Antibody-recruiting molecules: an emerging paradigm for engaging immune function in treating human disease. ACS Chem Biol. 7(7):1139-1151 (2012).
[cited by applicant]
Mei et al. FBXO32 Targets c-Myc for Proteasomal Degradation and Inhibits c-Myc Activity. J Biol Chem 290:16202-16214 (2015).
[cited by applicant]
Miyata et al. Polymer nanotechnology for nucleic acid delivery. Drug Delivery System 31(1):44-53 (2016) (English Abstract).
[cited by applicant]
Morgan et al. Human gene therapy. Ann Rev Biochem 62:191-217 (1993).
[cited by applicant]
Morrison et al. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. PNAS USA 81(21):6851-6855 (1984).
[cited by applicant]
Mulligan et al. Selection for animal cells that express the
[cited by applicant]
Mulligan. The basic science of gene therapy. Science 260(5110):926-932 (1993).
[cited by applicant]
Naisbitt et al. Disposition of amodiaquine and related antimalarial agents in human neutrophils: implications for drug design. J Pharmacol Exp Ther 280:884-893 (1997).
[cited by applicant]
Nakamura et al. Follow-up of three patients with a large in-frame deletion of exons 45-55 in the Duchenne muscular dystrophy (DMD) gene. J. Clin. Neurosci. 15:757-763 (2008).
[cited by applicant]
Neuberger et al. Recombinant antibodies possessing novel effector functions. Nature 312(5995):604-608 (1984).
[cited by applicant]
Normand-Sdiqui et al. Oligonucleotide delivery: Uptake of rat transferrin receptor antibody (OX / 26) conjugates into an in vitro immortalised cell line model of the blood, brain barrier. Int J Pharmaceuticals 163:63-71…
[cited by applicant]
Obika et al. Synthesis of 2′-0,4′-C-methyleneuridine and -cytidine. Novel bicyclic nucleosides having a fixed C3′-endo sugar puckering. Tetrahedron Lett. 38(50):8735-8738 (1997).
[cited by applicant]
O'Hare et al. Transformation of mouse fibroblasts to methotrexate resistance by a recombinant plasmid expressing a prokaryotic dihydrofolate reductase. PNAS USA 78:1527-1531 (1981).
[cited by applicant]
PCT/US2018/012672 International Search Report and Written Opinion dated May 24, 2018.
[cited by applicant]
PCT/US2018/012672 Invitation to Pay Additional Fees dated Mar. 20, 2018.
[cited by applicant]
PCT/US2018/052289 International Search Report and Written Opinion dated Jan. 11, 2019.
[cited by applicant]
PCT/US2020/029731 International Invitation to Pay Additional Fees dated Aug. 3, 2020.
[cited by applicant]
PCT/US2020/029731 International Search Report and Written Opinion dated Oct. 6, 2020.
[cited by applicant]
Perrault et al. Mixed deoxyribo- and ribo-oligonucleotides with catalytic activity. Nature 344:565-568 (1990).
[cited by applicant]
Pieken et al. Kinetic characterization of ribonuclease-resistant 2′-modified hammerhead ribozymes. Science 253:314-317 (1991).
[cited by applicant]
Rozema et al. Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes. PNAS USA 104(32):12982-12987 (2007).
[cited by applicant]
Santerre et al. Expression of prokaryotic genes for hygromycin B and G418 resistance as dominant-selection markers in mouse L cells. Gene 30(1-3):147-156 (1984).
[cited by applicant]
Schnyder et al. Targeting of skeletal muscle in vitro using biotinylated immunoliposomes. Biochem J 377(Pt.1):61-67 (2004).
[cited by applicant]
Schwarz et al. Evidence that siRNAs function as guides, not primers, in the
[cited by applicant]
Sekyere et al. Examination of the distribution of the transferrin homologue, melanotransferrin (tumour antigen p97), in mouse and human. Biochimica et Biophysica Acta 1722(2):131-142 (2005).
[cited by applicant]
Singh et al. Recent developments in oligonucleotide conjugation. Chem Soc Rev 39(6):2054-2070 (2010).
[cited by applicant]
Skerra et al. Assembly of a functional Immunoglobulin Fv fragment in
[cited by applicant]
Strop et al. Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates. Chem Biol 20(2):161-167 (2013).
[cited by applicant]
Sugo et al. Development of antibody-siRNA conjugate targeted to cardiac and skeletal muscles. J Control release 237:1-13 (2016).
[cited by applicant]
Summerton, et al. Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Dev. Jun. 1997;7(3):187-95.
[cited by applicant]
Sune-Pou et al. Targeting Splicing in the Treatment of Human Disease. Genes 8:E87 (2017).
[cited by applicant]
Suriano et al. Beta-catenin (CTNNB1) gene amplification: a new mechanism of protein overexpression in cancer. Genes Chromosomes Cancer 42(3):238-246 (2005).
[cited by applicant]
Suzuki et al. Endogenous Multiple Exon Skipping and Back-Splicing at the DMD Mutation Hotspot. Int JMol Sci. 17(10):1722 (2016).
[cited by applicant]
Szybalska et al. Genetics of human cell line. IV. DNA-mediated heritable transformation of a biochemical trait. PNAS USA 48:2026-2034 (1962).
[cited by applicant]
Takeda et al. Construction of chimaeric processed immunoglobulin genes containing mouse variable and human constant region sequences. Nature 314(6010):452-454 (1985).
[cited by applicant]
Talasila et al. EGFR Wild-type Amplification and Activation Promote Invasion and Development of Glioblastoma Independent of Angiogenesis. Acta Neuropathol. 125(5):683-698 (2013).
[cited by applicant]
Tolstoshev. Gene Therapy, Concepts, Current Trials and Future Directions. Ann. Rev. Pharmacol. Toxicol. 32:573-596 (1993).
[cited by applicant]
U.S. Appl. No. 16/128,450 Miscellaneous Communication re: Third Party Submission dated Jul. 1, 2019.
[cited by applicant]
U.S. Appl. No. 16/128,450 Office Action dated Apr. 19, 2019.
[cited by applicant]
U.S. Appl. No. 16/128,450 Office Action dated Apr. 30, 2020.
[cited by applicant]
U.S. Appl. No. 16/128,450 Office Action dated Dec. 16, 2020.
[cited by applicant]
U.S. Appl. No. 16/128,450 Office Action dated Sep. 19, 2019.
[cited by applicant]
U.S. Appl. No. 16/129,696 Miscellaneous Communication re: Third Party Submission dated Jul. 3, 2019.
[cited by applicant]
U.S. Appl. No. 16/129,696 Office Action dated Apr. 13, 2020.
[cited by applicant]
U.S. Appl. No. 16/129,696 Office Action dated Apr. 17, 2019.
[cited by applicant]
U.S. Appl. No. 16/129,696 Office Action dated Dec. 14, 2020.
[cited by applicant]
U.S. Appl. No. 16/129,696 Office Action dated May 26, 2021.
[cited by applicant]
U.S. Appl. No. 16/129,696 Office Action dated Sep. 19, 2019.
[cited by applicant]
U.S. Appl. No. 16/649,572 Miscellaneous Communication re: Third Party Submission dated Mar. 19, 2021.
[cited by applicant]
U.S. Appl. No. 17/463,473 Office Action dated Dec. 13, 2021.
[cited by applicant]
U.S. Appl. No. 17/463,484 Office Action dated Jan. 4, 2022.
[cited by applicant]
Usman et al. Exploiting the chemical synthesis of RNA. Trends Biochem Sci 17:334-339 (1992).
[cited by applicant]
Valtorta et al. KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy. Int J Cancer 133:1259-1266 (2013).
[cited by applicant]
Van Deutekom et al. Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells. Hum Mol Genet. 10(15):1547-54 (2001).
[cited by applicant]
Van Vliet et al. Assessment of the feasibility of exon 45-55 multiexon skipping for duchenne muscular dystrophy. BMC Medical Genetics 9:105 (2008).
[cited by applicant]
Verma et al. Modified oligonucleotides: synthesis and strategy for users. Annu Rev Biochem 67:99-134 (1998).
[cited by applicant]
Walker et al. Improved cellular delivery of antisense oligonucleotides using transferrin receptor antibody-oligonucleotide conjugates. Pharmaceutical research 12(10):1548-1553 (1995).
[cited by applicant]
Ward et al. Binding activities of a repertoire of single immunoglobulin variable domains secreted from
[cited by applicant]
Watts et al. Chemically modified siRNA: tools and applications. Drug Discov Today 13(19-20):842-855 (2008).
[cited by applicant]
Wigler et al. Transfer of purified herpes virus thymidine kinase gene to cultured mouse cells. Cell 11:223-232 (1977).
[cited by applicant]
Wigler et al. Transformation of mammalian cells with an amplifiable dominant-acting gene. PNAS USA 77:3567-3570 (1980).
[cited by applicant]
Winkler. Oligonucleotide conjugates for therapeutic applications. Ther Del 4(7):791-809 (2013).
[cited by applicant]
Wong et al. Co-injection of a targeted, reversibly masked endosomolytic polymer dramatically improves the efficacy of cholesterol-conjugated small interfering RNAs in vivo. Nucleic Acid Ther 22(6):380-390 (2012).
[cited by applicant]
Wu et al. Building complex glycopeptides: Development of a cysteine-free native chemical ligation protocol. Angew. Chem. Int. Ed. 45:4116-4125 (2006).
[cited by applicant]
Wu et al. Cell-penetrating peptides as transporters for morpholino oligomers: effects of amino acid composition on intracellular delivery and cytotoxicity. Nucleic Acids Res 35(15):5182-5191 (2007).
[cited by applicant]
Wu et al. Delivery systems for gene therapy. Biotherapy 3:87-95 (1991).
[cited by applicant]
Wu et al. Site-specific chemical modification of recombinant proteins produced in mammalian cells by using the genetically encoded aldehyde tag. PNAS USA 106(9):3000-3005 (2009).
[cited by applicant]
Xia et al. Intravenous siRNA of brain cancer with receptor targeting and avidin-biotin technology. Pharm Res 24(12):2309-16 (2007).
[cited by applicant]
Xu et al. Delivery systems for siRNA drug development in cancer therapy. Asian Journal of Pharmaceutical Sciences 10(1):1-12 (2015).
[cited by applicant]
Yessine et al. Characterization of the membrane-destabilizing properties of different pH-sensitive methacrylic acid copolymers. Biochimica et Biophysica Acta 1613:28-38 (2003).
[cited by applicant]
Yuan et al. Development of siRNA payloads to target KRAS-mutant cancer. Cancer Discov 4(10):1182-1197 (2014).
[cited by applicant]
Zhang et al. A remote arene-binding site on prostate specific membrane antigen revealed by antibody-recruiting small molecules. J Am Chem Soc. 132(36):12711-12716 (2010).
[cited by applicant]
Aartsma-Rus et al. Exploring the Frontiers of Therapeutic Exon Skipping for Duchenne Muscular Dystrophy by Double Targeting within One or Multiple Exons. Mol Ther 14(3):401-407 (2006).
[cited by applicant]
Echigoya et al. Multiple Exon Skipping in the Duchenne Muscular Dystrophy Hot Spots: Prospects and Challenges. J Pers Med 8(4):41 (2018).
[cited by applicant]
Echigoya et al. Skipping Multiple Exons of Dystrophin Transcripts Using Cocktail Antisense Oligonucleotides. Nucleic Acids Ther 24(1):57-68 (2014).
[cited by applicant]
Meregalli et al. Duchenne muscular dystrophy caused by a frame-shift mutation in the acceptor splice site of intron 26. BMC Med Genet 17(1):55 (2016).
[cited by applicant]
Rhodes et al. Bicyclic Peptides as Next-Generation Therapeutics. Chemistry 23(52):12690-12703 (2017).
[cited by applicant]
Shabanpoor et al. Bi-specific splice-switching PMO oligonucleotides conjugated via a single peptide active in a mouse model of Duchenne muscular dystrophy. Nucleic Acids Res. 43(1):29-39 (2015).
[cited by applicant]
Suter et al.: Double-target antisense U7 snRNAs promote efficient skipping of an aberrant exon in three human beta-thalassemic mutations. Hum Mol Genet 8(13):2415-2423 (1999).
[cited by applicant]
U.S. Appl. No. 16/649,572 Office Action dated Aug. 31, 2023.
[cited by applicant]
U.S. Appl. No. 17/843,705 Office Action dated Feb. 9, 2024.
[cited by applicant]
U.S. Appl. No. 18/052,899 Office Action dated Feb. 15, 2024.
[cited by applicant]
Vorobjev et al. Nuclease resistance and RNase H sensitivity of oligonucleotides bridged by oligomethylenediol and oligoethylene glycol linkers. Antisense Nucleic Acid Drug Dev 11(2):77-85 (2001).
[cited by applicant]
U.S. Appl. No. 16/649,572 Office Action dated Jul. 23, 2025.
[cited by applicant]
Wolfe, Justin M. et al. Perfluoroaryl bicyclic cell-penetrating peptides for delivery of antisense oligonucleotides. Angewandte Chemie International Edition 57(17):4756-4759 (2018).
[cited by applicant]